Unlocked Access
FULL SUPPLEMENT: A Novel Oral Treatment for Psoriasis: Deucravacitinib
February 2026 | Volume 25 | Issue 2 | Department | 070211s1 | Copyright © February 2026
INDIVIDUAL ARTICLE: Evidence-Based Synthesis of Deucravacitinib: Long Term Efficacy, Safety, and Practical Use in Moderate-to-Severe Psoriasis
February 2026 | Volume 25 | Issue 2 | Supplement Individual Articles | 070210s3 | Copyright © February 2026
Background: Deucravacitinib, a first-in-class, oral, selective TYK2 inhibitor, has redefined systemic therapy options for moderate-to-severe plaque psoriasis. This review synthes...
Read MorePractical Algorithm for Acne Treatment Integrating Skincare and Energy-Based Devices
February 2026 | Volume 25 | Issue 2 | Original Article | 111 | Copyright © February 2026
Background: Energy-based devices (EBDs) are increasingly used to manage acne and its sequelae. While literature supports the use of appropriate skin care for acne, few studies ad...
Read MoreEfficacy and Safety of Clascoterone Cream 1% for Acne Are Independent of Age and Sex
February 2026 | Volume 25 | Issue 2 | Original Article | 119 | Copyright © February 2026
Acne vulgaris is an inflammatory skin condition affecting adolescents and adults of both sexes. Clascoterone cream 1% is indicated for the topical treatment of acne vulgaris in patients ≥12 ye...
Read MoreWhat Drives the Aesthetic Journey? A Survey of the Cosmetic Concerns for African-American Women
February 2026 | Volume 25 | Issue 2 | Features | 181 | Copyright © February 2026
Treatment of Generalized Granuloma Annulare With Biologics and Oral JAK Inhibitors: A Case Series
February 2026 | Volume 25 | Issue 2 | Features | e26 | Copyright © February 2026
Reddit Discourse on Eczema: Quantitative Analysis of Misinformation, Engagement, and Alignment With 2025 American Academy of Dermatology Guidelines
February 2026 | Volume 25 | Issue 2 | Features | e30 | Copyright © February 2026
The Senile Cell: Understanding Cellular Senescence in Dermatology
February 2026 | Volume 25 | Issue 2 | Features | 189 | Copyright © February 2026
Real-World Effectiveness of Lebrikizumab for the Prurigo Nodularis–Like Phenotype of Atopic Dermatitis: A One-Year Retrospective Study
February 2026 | Volume 25 | Issue 2 | Editorials | e38 | Copyright © February 2026
Reducing Administrative Burden in Dermatology Through Compounding Alternatives
February 2026 | Volume 25 | Issue 2 | Editorials | e33 | Copyright © February 2026
GLP-1 Receptor Agonists in Overweight and Obese Patients With Hidradenitis Suppurativa
February 2026 | Volume 25 | Issue 2 | Features | 178 | Copyright © February 2026
Excimer Laser for Plaque Psoriasis: A Systematic Review and Meta-analysis
February 2026 | Volume 25 | Issue 2 | Editorials | e36 | Copyright © February 2026
Enhancing Patient Privacy in Dermatology: Best Practices for Image Organization and Security
February 2026 | Volume 25 | Issue 2 | Editorials | e35 | Copyright © February 2026
Dual IL-17A/F Blockade for Acrodermatitis Continua of Hallopeau: A Clinical Response to Bimekizumab
February 2026 | Volume 25 | Issue 2 | Case Reports | 172 | Copyright © February 2026
Acrodermatitis continua of Hallopeau (ACH) is a rare, localized variant of pustular psoriasis that primarily affects the distal digits and nail apparatus, often presenting with recurrent pustules...
Read MoreEvaluation of an Advanced, Multimodal Skin Tone Correcting Serum in Participants With Mild-to-Severe Dyschromia and Hyperpigmentation
January 2026 | Volume 25 | Issue 1 | Original Article | 36 | Copyright © January 2026
Background: A new multimodal skin tone correcting serum formulated with b.r.y.t.e.r. (brown, red, and yellow tones with enhanced resurfacing) technology (EV-I) targets brown, red...
Read MoreRacial and Ethnic Disparities in Access to Advanced Therapies for Atopic Dermatitis in the United States
January 2026 | Volume 25 | Issue 1 | Original Article | 54 | Copyright © January 2026
Background: Atopic dermatitis (AD) disproportionately affects diverse patient populations, and complex factors influence access to treatment among different racial and ethnic gro...
Read MoreClinical Evaluation of a Thiamidol-Based Regimen With SPF Compared With SPF Alone for Facial Hyperpigmentation
January 2026 | Volume 25 | Issue 1 | Original Article | 48 | Copyright © January 2026
Background: Hyperpigmentation disorders are common skin concerns that negatively impact patient quality of life and self-perception. Hyperpigmentation results from the overproduc...
Read MoreFULL SUPPLEMENT: Nordic European Cutaneous Oncodermatology Management (Necom) 7: Real-World Cases Applying Recommendations for the Prevention and Treatment of Skin Reactions Related to Cancer Therapies Using Skin-Protective Measures
December 2025 | Volume 24 | Issue 12 | Department | 508410s1 | Copyright © December 2025
The current risk of getting cancer before age 80 in Nordic countries is estimated at 42.7% in males and 36.2% in females. Based on the collaborative Nordic cancer registry (NORDCAN), breast, lung, and...
Read MoreFDA Boxed Warnings: Should Package Inserts Include Levels of Evidence?
December 2025 | Volume 24 | Issue 12 | Features | e67 | Copyright © December 2025
Many medications commonly used in dermatology come with package inserts that contain boxed warnings that are frequently not evidence-based. Boxed warnings are the most serious warnings that the U...
Read MoreINDIVIDUAL ARTICLE: NECOM 7: Real-World Cases on Preventive and Treatment Using Skin Care for Cancer Treatment-Related Skin Reactions
December 2025 | Volume 24 | Issue 12 | Supplement Individual Articles | 50842s3 | Copyright © December 2025
As cancer prevalence continues to increase in Nordic countries, the amount of dermatological adverse events, termed cutaneous adverse events (cAEs), will also increase. The Nordic European Cutane...
Read More© 2026 Journal of Drugs in Dermatology. All Rights Reserved. JDD, a peer-reviewed, MEDLINE®/PubMed® indexed journal, offers the dermatology community strong content of utmost quality and relevance on drugs, devices, and methods.
